USFDA11 Sept 2026, 01:43 pm
Senores Pharma Subsidiary's USFDA Inspection Concluded
AI Summary
Senores Pharmaceuticals Ltd announced that its subsidiary, Apnar Pharma Private Limited, located in Vadodara, has successfully completed its USFDA inspection. The inspection took place from September 7-11, 2026. Notably, there were no GMP-related observations, with only one minor procedural observation noted. Apnar Pharma will submit its response within the stipulated timeframe. This successful inspection is a positive development for the subsidiary's manufacturing capabilities and regulatory compliance.
Key Highlights
- USFDA inspection at subsidiary Apnar Pharma facility completed.
- No GMP-related observations were reported.
- One minor procedural observation was noted.
- Subsidiary to submit response within timeframe.
Price Impact
More from SENORES